Objective:To explore the effect of nutrition intervention on patients with cervical cancer undergoing chemoradiotherapy.Methods:From October 2016 to October 2018, 60 patients with cervical squamous cell carcinoma confirmed by pathology and treated with radiotherapy and chemotherapy in the First Hospital of Shanxi Medical University were selected. The subjects were randomly divided into the control group (nutrition education + dietary guidance only, 30 cases) and the intervention group (nutrition intervention according to nutrition assessment results, 30 cases) by random number table method. The nutrition assessment for patients was performed with patient-generated subjective global assessment (PG-SGA) scale. The changes of nutrition status, quality of life, incidence of adverse reactions, interruption status of radiotherapy and chemotherapy, and hematological indexes between the two groups in the treatment process were compared.Results:The incidence of moderate and severe malnutrition in the control group and the intervention group in the treatment process was 90% (27/30) and 50% (15/30), respectively, and the difference was statistically significant ( P < 0.01). When the dose of radiotherapy reached 40 Gy, the quality of life of patients in the intervention group was better than that in the control group in some functional fields, symptom fields and overall health status, and the differences were statistically significant (all P < 0.05). The incidence of acute gastrointestinal reaction in the control group and the intervention group was 96.7% (29/30) and 83.3% (25/30), respectively, and the incidence of bone marrow suppression was 96.7% (29/30) and 76.7% (23/30), respectively, and there were statistical differences in the incidence rates of different degrees of acute gastrointestinal reaction and bone marrow suppression between the two groups (both P < 0.05). The interruption rate of radiotherapy in the control group and the intervention group was 26.7% (8/30) and 6.7% (2/30), respectively, and the interruption rate of chemotherapy was 56.0% (14/25) and 26.9% (7/26), respectively, and the differences between the two groups were statistically significant (both P < 0.05). The cycles of chemotherapy completed in the intervention group were more than those in the control group [(4.38±1.10) cycles vs. (3.44±1.58) cycles]. The differences of peripheral blood red blood cells count, hemoglobin, albumin, and total protein between the control group and the intervention group before and after treatment were statistically significant (all P < 0.05), and the decreased values in the intervention group were lower than those in the control group. Conclusion:Nutrition intervention can effectively improve the nutrition status and quality of life of patients with cervical cancer undergoing chemoradiotherapy, reduce the incidence of adverse reactions, chemoradiotherapy interruption rate and decline degree of hematological indexes.

Objective:To assess the feasibility and efficacy of hypofractionated radiotherapy with simultaneous integrated boost (HFRT-SIB) for patients with non-osteogenic spinal metastases who were not suitable for stereotactic body radiotherapy (SBRT).Methods:A totoal of 26 spinal metastatic lesions in 24 patients with non-osteogenic spinal metastases admitted to Beijing Luhe Hospital affiliated to Capital Medical University from March 2020 to April 2023 were retrospectively analyzed. In our institution, a higher-dose fractionated regimen for spinal metastases was introduced, at a dose of 3 Gy/f ×10 times (5 times a week, once a day) to the clinical target volume (CTV), and simultaneous integrated boost (SIB) of 4 Gy/f ×10 times (5 times a week, once a day) to the gross tumor volume (GTV). The primary endpoint was the overall relief (OR) rates of pain at 12 and 24 weeks post-radiotherapy, while secondary endpoints included the pain response time and duration of pain relief, the incidence of adverse events post-radiotherapy, and the 1-year overall survival (OS) rate. The differences before and after treatment were analyzed by Wilcoxon signed-rank test. OS was assessed using Kaplan-Meier method.Results:The median follow-up was 11.7 (8.0, 17.0) months. At 12 weeks post-radiotherapy, 92% (22/24) of patients achieved OR, and 81% (17/21) obtained OR at 24 weeks post-radiotherapy. The median pain response time was 4 (3, 5) d. At the last follow-up, 42% (10/24) of patients maintained pain relief for over 1 year, with a median duration of pain relief up to 11.0 (6.0, 16.9) months. The 1-year OS rate was 66.3%, and no patients experienced grade 3 or higher acute or chronic adverse events.Conclusion:HFRT-SIB can effectively alleviate pain, and achieve sustained pain control, and does not lead to severe adverse effects in patients with non-osteogenic spinal metastases.